ARTICLE | Clinical News
CBP501 regulatory update
January 16, 2012 8:00 AM UTC
FDA granted Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas expects to complete a Phase II trial evaluating the product plus cispl...